In light of exceptional protein-holding capacity and superior immunostimulatory activity of the large HSPs (Hsp110, Grp170), we have created recombinant heat shock vaccines by complexing clinically relevant tumor protein antigens to these large chaperones (74, 108–112). This evidence concerns the gene HYOU1 and neoplasm.